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Abstract
Objective—Since limited data exist on adults with Prader-Willi syndrome (PWS) and growth
hormone (GH) treatment, we report our experience on the effects of treatment for one year on
body composition, physical activity, strength and energy expenditure, diet, general chemistry and
endocrine data with quality of life measures.
Design—We studied 11 adults with PWS (6F:5M; average age = 32 yrs) over a 2 year period
with GH treatment during the first year only. Electrolytes, IGF-I, glucose, thyroid, insulin, lipids,
body composition, physical activity and strength, diet, energy expenditure and quality of life data
were collected and analyzed statistically using linear modeling at baseline, at 12 months following
GH therapy and at 24 months after treatment cessation for 12 months.
Results—Total lean muscle mass was significantly increased (p < 0.05) during GH treatment
along with moderate-vigorous physical activity and plasma IGF-I and HDL levels, but returned to
near baseline after treatment. Percent body fat decreased during the 12 months of GH treatment
but increased after treatment.
Conclusions—Previously reported beneficial effects of GH treatment in children with PWS
were found in our adults regarding body composition, physical activity and plasma HDL and IGF-
I levels. Several beneficial effects diminished to near baseline after cessation of GH treatment for
12 months supporting the continuation of treatment in PWS into adulthood and possibly adults not
previously treated during childhood.
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Introduction
Prader-Willi syndrome (PWS) is a complex genomic imprinting disorder affecting multiple
body systems including hypotonia, poor suck and feeding problems, hypogonadism/
hypogenitalism, growth hormone (GH) deficiency with short stature and small hands/feet,
hyperphagia and obesity, learning/behavior problems and a characteristic face.1–5 PWS is
due to absence of paternally expressed genes in the 15q11-q13 chromosome region from a
deletion, maternal disomy 15 or an imprinting defect.2, 3, 6
Children with PWS grow at different rates than other children but most are born with a
normal weight and length. Failure to thrive occurs but they gradually gain strength and
muscle mass before onset of hyperphagia and obesity in early childhood. The fat mass
increases more rapidly than muscle mass or stature in children with PWS without growth
hormone treatment with more than twice the amount of body fat gained compared with
others and often measuring about 50% of their total body weight.7 Weight control with
exercise and dietary restrictions are key management issues.2,8,9
Due to growth hormone deficiency reported in PWS, the Food and Drug Administration
approved treatment in children genetically confirmed with PWS in 2000 without prior
laboratory determination of growth hormone deficiency. GH treatment is now commonly
prescribed in infancy and childhood to increase stature in PWS but also increases muscle
and decreases fat thereby lowering risk factors for diabetes and cardiopulmonary problems.
Increased alertness, physical activity and self-esteem in older children are potential effects
of GH treatment10–15 which should improve the quality of life applicable in adulthood. In
addition, Lindgren and Lindberg16 documented that GH treatment in children with PWS
appear to normalize to an adult height with improvement in body composition, an important
outcome for individuals with this disorder. PWS children appear to be highly sensitive to
GH suggesting that growth factors (i.e., insulin-like growth factor I or IGF-I) should be
monitored closely (e.g., every three months) and maintained within the normal range for
age. There is a paucity of data on the use of GH in adults with PWS not previously treated
and related to energy expenditure, physical activity, body composition, endocrine and
quality of life measures.
The main objective of our study was to examine how GH treatment for one year would
impact on body composition, quality of life, physical activity and energy balance in adults
with PWS using novel approaches, and if loss of a positive effect, if present, during therapy
disappears after cessation of treatment for 12 months. Anticipated outcomes:
1. Increase IGF-I level thereby lessoning risk factors for co-morbidity; improve
quality of life measures; decrease fat, increase lean body mass and bone density
determined by DEXA.
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2. Increase energy expenditure as determined by whole-room calorimeter measures,
diet records, physical activity monitors, strength and endurance measures.
Materials and Methods
Subjects
We screened 12 genetically confirmed Caucasian adults with PWS and enrolled 11 adults
(6F:5M; average age ± SD = 32.3y ± 11.1y; age range = 23y to 50y) for a non-controlled
two year study on the effects of GH treatment for 12 months followed by an observation
period of 12 months without treatment. The inclusion criteria for selection were as follows:
Sixteen to 60 years of age; male or female with diagnosis of PWS confirmed by genetic
testing; low plasma IGF-I level (e.g.,<25%ile) at baseline; and ability to provide informed
consent or availability of a suitable legally authorized representative. The exclusion criteria
were as follows: Pregnancy; previous GH treatment; untreated or uncontrolled endocrine
disease (e.g., diabetes or thyroid disorder); history of severe scoliosis; uncontrolled high
blood pressure, heart disease or history of stroke; weight greater than 95%ile based on
gender and established age specific growth charts for PWS17) and severe breathing problems
by history or sleep apnea found by sleep center polysomnography as a diagnostic tool used
in sleep medicine. The adults with PWS enrolled in the study showed evidence of
hypogonadism (i.e., males with small, undescended testicles and females with absent or
sparse history of menstruation) with low plasma estrogen or testosterone levels.
The subjects were recruited from a multi-disciplinary clinic specializing in PWS directed by
one of the authors (MGB) following informed consent with the study protocol approved by
the local institutional review board. Height and weight were determined at each visit. Height
(measured to the nearest 0.1 cm using a Forgue electric stadiometer) and weight (measured
to the nearest 0.1 kg using a calibrated electronic scale, height) were obtained by one of the
authors (CS). Heights that were discordant from previous measurements were confirmed by
repeat measurement. Variations in height were attributed to lack of cooperation by the
subjects. Age, weight, height, body mass index (BMI kg/m2), percent body fat and energy
expenditure data are shown in Table 1. Nine PWS adults had the typical 15q11-q13 deletion;
one with maternal disomy 15 and one with an imprinting defect determined by genetics
testing.4, 5 During this study, daily subcutaneous injections of growth hormone (e.g.,
Genentech Nutropin AQ; 0.0125 mg/kg/day) were administered which were comparable to
dosages reported previously in PWS adults and based on the treatment of adult GH
deficiencies.18 Each subject and care provider underwent training for GH administration,
recording of dosage and monitoring for potential side effects (edema, headaches and signs of
allergic reactions). Compliance for growth hormone use was determined by monitoring the
amount of GH unused in the kit when returned at each scheduled clinic visit (e.g., monthly).
At the time of the physical examination and measurements, blood was collected for
laboratory studies before a new package of GH and administration supplies were given to
the subject for continuation of treatment. Growth hormone dosages were adjusted in the first
3 months of treatment to achieve plasma IGF-I levels within the therapeutic reference range
for at least 9 months during the first year. Each assessment was undertaken over a two year
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period (at baseline, at 12 months of GH therapy and at 24 months or one year following
treatment).
Methods
Fasting Blood Samples and Body Composition Measures—Fasting blood samples
were obtained for general chemistry (electrolytes), plasma IGF-I, glucose, thyroid, insulin
and lipid levels at screening, baseline, 1 month, 2 months, 3 months, 6 months, 9 months, 12
months and 24 months using established protocols in the Children’s Mercy Hospital
clinically approved certified laboratories for patient care. Due to hyperphagia and food
seeking behavior as major components of PWS, the fasting status of each subject could not
be confirmed for all measurements. Dual energy x-ray absorptiometry (DEXA – General
Electric Prodigy, Atlanta, GA) was used to determine body composition (lean muscle and
fat) and bone mineral density following established protocols.19 Provocative growth
hormone stimulation testing was not performed prior to enrolling in the study. All subjects
were healthy and not undergoing medical care for chronic illnesses related to their disorder.
Dietary Intake—All participants were asked to complete a 3-day food record with the
assistance of their care provider in order to determine the average caloric intake. Because of
the range of cognitive abilities in individuals with PWS and their food seeking behavior,
obtaining accurate measurements of dietary intake would be difficult. Thus, to increase the
accuracy of caloric intake, the 3-day food records were sent to the participant as well as the
primary caregiver for completion. The primary caregiver was asked to assist each participant
in recording all foods consumed during 3 days (2 week days and 1 weekend day). Primary
caregivers were provided detailed instructions on completion of the 3-day food records and
were asked to track all food consumption during the three day periods. To increase accuracy
of the records, caregivers were asked to provide labels and/or packaging from all packaged
foods. Upon completion, registered dietitians followed up with the participants to ensure the
accuracy of the records and reviewed the records for completeness and nutrient calculations
performed on the recorded data using the Nutrition Data System for Research Software 2010
(University of Minnesota, Minneapolis, MN).
Strength Index—Voluntary physical activity was measured by CSA accelerometers and
strength by the one repetition of maximum method (1RM) with two exercises (bench and leg
press) on all subjects following established protocols.20 Assessments of muscular strength
(assessed by 1RM) were obtained at baseline, at 12 and 24 months using bench press
(Paramount Fitness Corporation, Los Angeles, CA) and leg press (Hammer Strength, Shiller
Park, IL) according to the protocol described by Lemmer et al.20 The participants initially
completed a light 5 repetition warm-up period with minimal weight. After a brief rest for 60
seconds, a weight estimated to be less than the participant’s 1RM was chosen and the
participant was instructed to lift the weight through a full range of motion. If the lift was
successful, the weight was increased then followed by a 60 second rest. They were then
asked to lift the increased weight again and 1RMs obtained in less than 5 lifts for exercise.
This procedure was repeated until a weight was reached that the participant could no longer
lift. The maximum weight lifted through the full range of motion was recorded as their
1RM.
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Indirect Calorimeter and Metabolic Measurements—A whole-room indirect
calorimeter as described previously19,21 was used to continuously measure energy
expenditure over an 8 hour period at baseline, and at the end of year one following GH
treatment and at year two. Twenty-four hour energy expenditure was then extrapolated from
the 8 hour measurement.21
The completed 3-day food records were used to develop standardized menus to mimic the
participant’s habitual diet (kcal and macronutrient composition) while in the whole-room
calorimeter. Participants were asked to follow the menus for the 3 day period prior to their
baseline metabolic measurement which were used in the whole-room calorimeter. These
same menus were then provided to each participant prior to each subsequent visit and they
were asked to follow these menus during the 3 days prior to testing.
Participants entered the whole-room calorimeter at 8:00am and remained in the room until
4:00pm. Upon entering the calorimeter, participants were asked to lie quietly, but not sleep,
for the first 60 minutes of the whole-room stay in order to measure their resting metabolic
rate (RMR). The participants were then allowed to watch TV, read or play games while in
the room. They were not allowed to sleep while in the calorimeter. Research staff checked
on the participants at least every 30 minutes to ensure that the participants were awake.
Standardized meals scheduled to be consumed during the testing period were provided to the
participant at the appropriate times.
Urine was collected during the calorimeter stay for the determination of total nitrogen
concentration22 to assess protein oxidation.23,24 Using measured oxygen consumption and
carbon dioxide production, respiratory quotient (RQ), energy expenditure and substrate
oxidation were calculated using the equations of Jequier et al.25
Physical Activity Measurements—Daily physical activity was measured with
accelerometers [Actigraph GTM1 (Actigraph, Pensacola, FL)] at baseline and at year one
and year two and mailed to the participants with specific instructions on wearing the device
approximately 10 days prior to visit. Participants wore the accelerometer on a belt over their
non-dominant hip for seven consecutive days prior to their visit except when sleeping,
swimming or bathing. Upon arrival to the laboratory, the accelerometers were collected and
data downloaded. Data were collected in one-minute epochs and a minimum of 12 hours
required to be considered a valid monitored day. Intensity cut-points were based upon the
National Health and Nutrition Examination Survey reported by Troiano et al.26 with
sedentary (≤ 99 counts/minute), light (100 to 2019 counts/minute), moderate (2020 to 5999
counts/minute) and vigorous (≥ 6000 counts/min) recorded on each subject.
Quality of Life Assessments—Two quality of life instruments were selected for
administration to the PWS adults. The Quality of Life—Assessment of Growth Hormone
Deficiency in Adults (QoL-AGHDA) questionnaire was administered initially to the PWS
adults by one of the authors (BKS) by reading questions along with the possible choices to
each participant. No additional explanations of the study questions were required for each
subject to participate successfully in the assessments. The QoL-AGHDA is a 25-item
disease-specific instrument used to assess patients’ perceptions about their physical, social,
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and mental health for adults with growth hormone deficiency.27,28 A total score was
produced by summing across all items; a higher QoL-AGHDA score indicates a poorer
quality of life. This instrument has been shown to be both reliable and valid with a high
level of internal consistency. The short form (SF) – 36 was also used which is a validated
self-administered questionnaire that assesses eight health dimensions, including physical
functioning, role limitations related to physical functioning, general health perception,
vitality, pain, social functioning, emotional well-being and role limitations due to emotional
health.29 Dimension scores were standardized between 0 and 100, with higher scores
representing a better quality of life and previously used on individuals with cognitive
impairment without comprising reliability and validity30 and also utilized with GH-treated
PWS adults.31 The SF-36 scale was also administered at baseline, at 12 months following
growth hormone therapy and at 24 months after one-year cessation from growth hormone
treatment.
Data Analysis
Our primary endpoint was the longitudinal comparisons of body composition, blood
chemistry and physical activity measures between different stages of growth hormone
treatment over a 2-year period (baseline, at 12 months while on GH treatment and at 24
months after treatment). We used mixed modeling32 to handle non-independence of the data
where the outcome measures were collected at multiple time points. The model effects and
the error covariance components for the repeated measures were estimated using the
restricted maximum likelihood (REML) procedure. In the mixed models, total lean gram,
total percent body fat, average counts of moderate-vigorous bouts per day, average length of
moderate-vigorous bouts per day, IGF-I, HDL and quality of life scores were contrasted
between three measurement periods (baseline, 12 months, 24 months) adjusting for the
participants’ gender. The compound symmetry error structure provided a smaller AIC
[(Akaikes information criteria) or model fit index used to select a model among a finite set
of models] and BIC score [(Bayesian information criteria) or another model fit index used
for model selection, which introduces a penalty term for the number of parameters in the
model] than did the completely general (unstructured), first-order autoregressive and
variance component error structures and thus chosen for the model system. All analyses
were conducted using SAS 9.231 (SAS Institute, Cary, NC).
Results
The data were analyzed using mixed modeling to handle interdependency among
observations and descriptive characteristics grouped by gender (Table 1). All PWS adults
(45% were male) were Caucasian with an average age (±SD) of 32.3y±11.1y. Figure 1
presents the adjusted means of each outcome measure at baseline, 12 months and 24 months.
In the mixed model system, total lean gram, number of bouts of moderate-vigorous physical
activity per day, the average plasma IGF-I levels, which were low or outside the reference
range at baseline in our subjects and HDL levels were increased during the growth hormone
treatment phase of the study (baseline to 12 months), but after treatment (12 to 24 months)
the measures decreased back to baseline levels. The adverse events that might be related to
growth hormone therapy included one episode of mild edema of the lower leg in a single
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patient (50 year old male) during the first month of GH treatment which stabilized during
the rest of the treatment period and impaired glucose tolerance in four subjects defined as
one plasma glucose level over 100mg/dl. The average pretreatment plasma glucose level in
these subjects was 82 ± 6mg/dl before and 99 ± 22mg/dl during GH treatment. In all
instances, the elevated glucose level was sporadic. One individual had a plasma glucose
level over 100mg/dl (i.e., 102mg/dl) before GH treatment and impaired glucose tolerance
noted during treatment. A second individual had a plasma glucose level over 100mg/dl (i.e.,
102mg/dl) before GH treatment and normal plasma glucose during treatment. All subjects
with impaired glucose tolerance during the treatment phase had normal plasma glucose on
follow-up measurements. One individual had well controlled type 2 diabetes and the overall
glycemic control did not deteriorate during treatment. The remainder of the subjects had
glucose levels less than 100mg/dl before, during, and after treatment. The elevated plasma
glucose levels did not correlate with the plasma IGF1 levels. The participants lowered their
total percent body fat during the first 12 months of GH treatment, but they regained a fat
mass more than what they reduced during the 12 months following GH treatment. These
changes were significant at 0.05 alpha level, except for the moderate-vigorous physical
activity changes from 12 to 24 months and pain and HDL changes from baseline to 12
months. There were no significant differences between time points for diet records, resting
metabolic rate, 8 hour energy expenditure or respiratory quotient (Table 2).
Discussion
Growth hormone replacement in children with PWS has well-defined benefits and risks,
although data are limited for adults with PWS. However, adults with PWS share similarities
with GH deficient patients (GHD) regarding reduced lean body mass (LBM) and increased
fat mass (FM). GH treatment in non-PWS GHD adults improves body composition and has
beneficial effects on muscle strength and physical performance. The reports on GH
treatment in adults with PWS, to date, indicate improved body composition with increased
LBM, a reduction in total body fat, subcutaneous adiposity and visceral fat but with small
increases in fasting glucose after 12 months of treatment.33 Positive effects of GH treatment
on cognitive functioning were noted with improved verbal reasoning and visuospatial skills
and motor performance in children.34–36
We report a novel approach in PWS by measuring energy balance and comparing data
obtained from a monitored whole room calorimeter, daily physical activity measures and
quality of life assessments. Quality of life assessments (i.e., SF-36) were recorded in
relationship to repeated body composition, blood chemistry and hormone levels, dietary
records and strength indices in the selected PWS adults at baseline, after 12 months of GH
treatment and at 24 months while off GH treatment for 12 months.
Other GH treatment trials reported in PWS men and women included randomized treatment
with GH or a placebo for one year followed for two years with open-labeled GH
treatment.37 At one year, IGF-I levels were increased by 1.5 fold and body composition
improved. We also observed an increase (about 4 fold) over baseline in plasma IGF-I levels
after 12 months of GH treatment. Positive effects on body composition (i.e., decreased
visceral and thigh fat and increased muscle mass) were reported by Sode-Carlsen et al.37–39
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in their Scandinavian cohort of PWS adults after two years of GH treatment. The beneficial
effects occurred without serious adverse events while lipid and glucose metabolism data
were unchanged. We also observed the positive impact on body composition with decreased
total percent body fat after GH treatment but returned to near baseline after treatment
cessation for 12 months. One of our PWS males did experience mild leg edema during
treatment. High density lipoprotein levels did increase in our PWS adults during GH
treatment but returned to a lower (less beneficial) level after treatment cessation.
Mogul et al.18 in 2008 reported the effectiveness and safety of GH in 38 GH-deficient PWS
adults with a mean age of 30.5 years over a 12-month period using both six-month dose-
optimization and six-month stable treatment periods. Human recombinant GH was initially
administered at 0.2 mg/day with monthly 0.2 mg increments to a maximum of 1.0mg/day, as
tolerated, comparable to the dosage used in our study. They reported that lean body mass
increased by about 3 kg and percent body fat decreased by 3% in their 30 PWS adults who
completed the 6–12 month trial of GH treatment. Mildly progressive ankle edema was the
most serious treatment adverse event reported in 5 of their 38 PWS adults. The total lean
body mass in our study increased significantly by 2.3 kg during GH treatment but returned
to a near baseline level after cessation of treatment for 12 months. The mean fasting glucose
and insulin levels in their study were normal at baseline and remained in the normal
reference range during GH treatment which agreed with the results found in our study.
Although glucose levels were higher at 12 months of GH treatment in our PWS adults
compared to baseline (e.g., 116 vs 101 mg/dl, respectively), the levels were not significantly
different (see Table 2). No PWS adults in our study were diagnosed with diabetes during
GH treatment.
In a separate study, Angulo et al.40 in 2007 evaluated the final adult height in children with
PWS and with and without GH. They found that administration of growth hormone in
infancy and/or early childhood restored linear growth and final adult height without
significant adverse events. In contrast, children with PWS who had not received growth
hormone treatment had a significant decrease in growth velocity, with a mean final adult
height under 2 standard deviations below the relevant population mean and with a higher
risk for type 2 diabetes mellitus.
Lastly, endocrine and metabolic aspects of adults with PWS were studied by Hoybye41 in
2004 with special emphasis on the effect of growth hormone on a cohort of 19 young adults
with clinical PWS having a mean BMI of 35 kg/m2. At baseline the activity of the GH-IGF-I
system was impaired and bone mineral density was low, as similarly seen in our PWS
adults. Seventeen adults with PWS subsequently completed 12 months of GH treatment
without significant adverse effects. Their study showed that adults with PWS had a partial
GH deficiency, and GH treatment showed beneficial effects on body composition in adults
with PWS without significant side-effects.
Bertella et al.31 reported their experience with quality of life measures in a study of 13
adults with PWS treated with GH using the SF-36 quality of life instrument to assess eight
health dimensions. They found significant improvements with GH treatment in physical
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functioning, body pain and general mental health. We also recorded higher scores for 4 of
the 8 health dimension variables tested during GH treatment in our PWS study.
In conclusion, our study on GH treatment in adults with PWS of both sexes showed a
positive impact on several variables including total lean gram weight, moderate-vigorous
bouts of physical activity and plasma IGF-I and HDL levels during the growth hormone
treatment interval but fasting glucose levels increased during treatment but not significantly
different compared with baseline. The average fasting glucose levels were also high (outside
of the normative reference range at 12 months) following GH treatment. The average
baseline insulin levels were also high in comparison to reference ranges for our PWS adults.
However, after cessation of GH treatment for 12 months, several variables returned close to
baseline levels. In contrast, our PWS adults showed lower total percent body fat after 12
months of growth hormone treatment, but they regained more body fat than what they lost
during the 12 months off treatment. All changes were significant at 0.05 alpha levels, except
for the number of moderate-vigorous bouts of spontaneous physical activity recorded
changes from 12 to 24 months and HDL levels from baseline to 12 months after GH
treatment. Considering the extremely low physical activity levels at baseline in the PWS
adults, the lack of change in the number of moderate-vigorous bouts of spontaneous physical
activity from 12 to 24 months can be viewed as a positive outcome. An increase in
moderate-vigorous spontaneous activity, regardless of size, has the potential to have positive
long term benefits on weight management and overall health. The quality of life instruments
were used to assess PWS adults receiving growth hormone and showed improvement with
higher scores recorded for 4 of the 8 variables tested between baseline and at 12 or 24
months implying improvement during GH treatment for emotional and physical health,
energy, social and particularly pain sensation. Interestingly, individuals with PWS are
known to have decreased pain sensation and the change in pain perception during GH
treatment will require further investigation.
There were no significant differences identified between time point measures for resting
metabolic rate, 8 hour energy expenditure, or respiratory quotient using the whole room
calorimeter despite an increase in lean body mass from the effects of GH treatment in our
study. In the literature, the energy requirement in non-PWS individuals for lean body mass
is estimated at about 15 to 25 kcal per kg per day42,43 and the lean body mass increased by
2.3 kg on average in our PWS adults following GH treatment. Therefore, the potential
increase in resting metabolic rate would be estimated at 34–57 kcal which would account for
little change in the resting metabolic rate detectable in our study. A second potential factor
to consider for the lack of difference in energy expenditure measures may be the testing
conditions. Although the whole room indirect calorimetry does allow for accurate
measurements of energy expenditure, the space restrictions may limit spontaneous physical
activity by the subject during the course of the day. Reduced spontaneous physical activity
due to space restrictions in the whole room chamber could result in lower 24 hour metabolic
rate calculations when compared to free-living arrangements outside of the chamber.
Several beneficial effects of growth hormone treatment noted previously in children with
PWS were also observed in our PWS adults, specifically improved body composition,
increased physical activity (number and duration of spontaneous bouts of activity or
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movement) and higher morning fasting plasma HDL (12 months compared with 24 months)
and IGF-I levels. Several of the measures appeared to regress to baseline after GH treatment
cessation for 12 months. Due to better recognition, care and treatment including prevention
of extreme obesity and co-morbidities, it is expected that GH treatment in PWS adults may
exceed 50 years as affected patients are now living to an advanced age. Our study is not
definitive due to sample size and length of treatment but supports the accumulating data on
the use of GH in treating PWS adults with or without prior GH therapy to produce beneficial
effects on body composition, physical activity, lipid profiles and possibly on quality of life
with minimal adverse effects but glucose and insulin levels should be followed during GH
treatment as recommended in treating non-PWS GH deficient patients. The authors do
encourage an expanded study with a larger group of patients including those at an older age
and obtain long term outcome data greater than two years duration on potential side effects
(e.g., increased glucose levels, insulin resistance, edema) before a firm decision can be made
regarding use of long term GH treatment and cost effectiveness in PWS adults. The
implications and cost of long term GH treatment to each individual and to society and added
health risks will warrant more investigation and discussion.
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Multiple Parameters Showing Significant Differences in Individuals with Prader-Willi
Syndrome Receiving Growth Hormone Treatment
*p < 0.05; **p < 0.01 for fixed effect within-subject (time) comparison using 12 months as a
reference point.
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Table 1
Baseline Descriptive Characteristics of Individuals with Prader-Willi Syndrome Grouped by Gender
Variable Females (N=6) Males (N=5)
Age (yrs) 33.8 ± 12.2 30.4 ± 10.9
Height (cm)** 144.7 ± 1.6 154.2 ± 2.5
Weight (kg)** 72.5 ± 5.4 98.9 ± 7.2
BMI 34.5 ± 2.2 41.6 ± 2.9
Percent Body Fat 51.0 ± 2.3 51.5 ± 2.9
24 hr EE (kcal)* 1 929 ± 124 2 654 ± 274
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